Shares of Dyax Corp. (Nasdaq: DYAX) 44% HIGHER; announced positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). Statistically significant results were achieved for both the primary and secondary endpoints in the EDEMA3 trial.
Krispy Kreme Doughnuts, Inc. (NYSE: KKD) 5% LOWER; said revenues for the fourth quarter decreased 8.2% to $112.2 million compared to $122.2 million in the fourth quarter of last year. The net loss for the fourth quarter was $24.4 million, or $0.39 per diluted share, compared to a net loss of $37.7 million, or $0.61 per diluted share, in the comparable period last year. The net loss for the quarter includes a charge related to the settlement of litigation of approximately $16.0 million. The Company recorded a $2.1 million provision for doubtful accounts. The Company recorded a $1.3 million charge related to the proposed settlement of certain wage and hour complaints.
Sirius Satellite Radio Inc. (NASDAQ: SIRI) 2.3% HIGHER; XM Satellite Radio (Nasdaq: XMSR) received from the Department of Justice a request for additional information and documentary material relating to our merger with Sirius Satellite.
Merck’s (NYSE: MRK) 1% LOWER; FDA panel votes 20 to 1 against Merck’s Arcoxia pain reliever.
Planar Systems (NASDAQ: PLNR) INDICATED LOWER; expects Q2 sales to be $53-$54 million and Non-GAAP net loss per share to be $0.07 to $0.09. Past guidance was for sales of $57-$61 million and Non-GAAP net income per diluted share of $0.04 to $0.07 and GAAP net loss per share of $0.06 to $0.09.
Shares of Dyax Corp. (Nasdaq: DYAX) 44% HIGHER; announced positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). Statistically significant results were achieved for both the primary and secondary endpoints in the EDEMA3 trial.
Krispy Kreme Doughnuts, Inc. (NYSE: KKD) 5% LOWER; said revenues for the fourth quarter decreased 8.2% to $112.2 million compared to $122.2 million in the fourth quarter of last year. The net loss for the fourth quarter was $24.4 million, or $0.39 per diluted share, compared to a net loss of $37.7 million, or $0.61 per diluted share, in the comparable period last year. The net loss for the quarter includes a charge related to the settlement of litigation of approximately $16.0 million. The Company recorded a $2.1 million provision for doubtful accounts. The Company recorded a $1.3 million charge related to the proposed settlement of certain wage and hour complaints.
Sirius Satellite Radio Inc. (NASDAQ: SIRI) 2.3% HIGHER; XM Satellite Radio (Nasdaq: XMSR) received from the Department of Justice a request for additional information and documentary material relating to our merger with Sirius Satellite.
Merck’s (NYSE: MRK) 1% LOWER; FDA panel votes 20 to 1 against Merck’s Arcoxia pain reliever.
Planar Systems (NASDAQ: PLNR) INDICATED LOWER; expects Q2 sales to be $53-$54 million and Non-GAAP net loss per share to be $0.07 to $0.09. Past guidance was for sales of $57-$61 million and Non-GAAP net income per diluted share of $0.04 to $0.07 and GAAP net loss per share of $0.06 to $0.09.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
